By securing P10 Billion Series C financing SoftBank Group, Heritage Provider Network, Irving Investors, and Highside Capital Management, Intervenn Biosciences will continue to develop and commercialize a blood-based test for cancer research. […]
Biotech firm InterVenn Biosciences raises P10 billion for cancer research
You must be logged in to post a comment.